NEBULA

Phase 2Small molecule

SSeoul National University Hospital

NEBULA is one of 14 small molecule programs targeting Waldenstrom macroglobulinemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Waldenstrom MacroglobulinemiaNot yet recruiting

Waldenstrom MacroglobulinemiaPhase 2

Not yet recruiting

Competition

Competitive Landscape

13 competitors in Waldenstrom Macroglobulinemia

#DrugCompanyPhaseTrials

Calquence

AstraZeneca

Approved

1 2

Venclexta

AbbVie

Approved

1 3

Afinitor

Ninlaro

Jaypirca

Brukinsa

2 7

Treanda

AAzurity Pharmaceuticals

Approved

2 8

Rituxan

Roche

Phase 3

7 9

Zocor

Farydak

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Not yet recruiting

Study completion

NCT07464210

Clinical

Trials by Indication[1]

Unspecified1 trial

Nemtabrutinib, Bortezomib, and Rituximab for WM

Not yet recruiting·SSeoul National University Hospital·Phase 2·NCT07464210·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NEBULA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NEBULA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NEBULA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSeoul National University Hospital

NEBULA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News